Implantable Left Ventricular Assist Device (LVAD) in addition to guideline directed medical therapy (GDMT) in end stage heart failure
Gillespie F, Abraha I, Amicosante AMV, Caimmi P, Chiarolla E, Corio M, Paone S, Jefferson T, Cerbo M
Record ID 32016000854
English
Authors' objectives:
To assess the effect of using a LVAD in addition to guideline directed medical therapy (GDMT) (including Cardiac Resynchronization Therapy Defibrillator, CRT-P, implantable cardioverter defibrillator ICD and Cardiac Resynchronization Therapy Defibrillator CRT-D) in adult patients with end stage heart failure who are not eligible or immediately eligible for cardiac transplant in stage D of the ABCD classification of the American College of Cardiology (ACC)/American Heart Association (AHA), and class III–IV of the New York Heart Association (NYHA) functional classification.
Authors' recommendations:
Continuous-flow LVAD represents a promising technology considering the shortage of donor hearts, the increase in survival and quality of life. The technology is the only alternative treatment in patients who are temporarily or definitively not eligible for transplant.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.salute.gov.it/imgs/C_17_pagineAree_1202_listaFile_itemName_10_file.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Italy
MeSH Terms
- Humans
- Heart Failure
- Heart-Assist Devices
Contact
Organisation Name:
The Italian National Agency for Regional Health Services (Agenas)
Contact Address:
Agenzia nazionale per i servizi sanitari regionali, Via Puglie 23, 00187 Rome, Italy
Contact Name:
hta@agenas.it
Contact Email:
hta@agenas.it
Copyright:
Italian Ministry of Health and Agenas
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.